When a public health system succeeds at drawing people in but fails to receive them, the promise of care becomes its own kind of harm. New Zealand's cervical screening programme found this out the hard way: a 2023 rollout of at-home HPV tests brought Māori and Pacific women into the system in meaningful numbers for the first time, only to leave many waiting in a diagnostic bottleneck that the country's colposcopy services were never resourced to absorb. The review released this week is less a story of policy failure than of a recurring human pattern — the gap between the vision of equity and t
NZ cervical screening system 'set up to fail' as HPV test rollout outpaces resources
Between 2018 and 2022, Māori women died from cervical cancer at more than twice the rate of other New Zealanders, highlighting health inequities in screening access and outcomes.
Set up to fail the women we are providing care to
Mark
So the HPV tests were supposed to be good news—more women getting screened, especially Māori and Pacific women who'd been left behind. What went wrong?
Mimi
The tests worked exactly as intended. Uptake jumped. But then those positive results had to go somewhere—colposcopy clinics, cytology labs. Those places were never staffed or equipped for the volume that came.
Luke
How much of a delay are we talking about? The report doesn't seem to give specific wait times.
Mimi
That's the thing—it doesn't. We know colposcopy is "overwhelmed," we know it's a problem, but the actual numbers aren't in the review.
Mark
And the screening register—the database that's supposed to track everyone—that's broken too?
Mimi
It can't even reach people the way they want to be reached. Text and email for Māori and Pacific communities, but the register doesn't do that. It's designed to help the hardest-to-reach populations and it's failing them.
Luke
But is that a design flaw or a resourcing problem? Could it be fixed?
Mimi
Probably both. The review doesn't say whether the register was built wrong or just never given the budget to do what it was supposed to do.
Mark
What about the Māori women dying at twice the rate—is that directly because of these screening failures?
Mimi
The review connects them. If you're not being screened, you're not catching cancer early. If you're screened but can't get a colposcopy appointment, the same thing happens.
Luke
But the data is from 2018 to 2022, and the HPV rollout was 2023. So those deaths predate the current crisis.
Mimi
Right. They show the historical inequity. The question now is whether the new system, if properly resourced, can actually close that gap.
Mark
Will it be?
Mimi
Both parties say they support universal free screening next year. But the review's real message is that screening only works if the whole pathway works. Right now it doesn't.
O Pulso
- A damning independent review has found that New Zealand's cervical screening programme was structurally unprepared for the surge in referrals that its own HPV self-test rollout was always going to generate.
- Colposcopy clinics, already operating at capacity, were flooded with positive-test referrals while staffing, equipment, and appointment slots remained unchanged — leaving women in diagnostic limbo at the moment they needed answers most.
- The national screening register, described by clinicians as 'clinically unsafe,' cannot identify under-screened populations or reach people by email or text, effectively making the system invisible to the communities it most needs to serve.
- Māori women died from cervical cancer at more than twice the rate of other New Zealanders between 2018 and 2022, a disparity the review places at the centre of its call for a Te Tiriti-led co-governance model — a recommendation the current Health Minister has rejected.
- Both major parties back universal free cervical screening next year, but the review's unresolved warning stands: a screening system that cannot resource its own downstream consequences is not a safety net — it is a false promise.
When a public health system succeeds at drawing people in but fails to receive them, the promise of care becomes its own kind of harm. New Zealand's cervical screening programme found this out the hard way: a 2023 rollout of at-home HPV tests brought Māori and Pacific women into the system in meaningful numbers for the first time, only to leave many waiting in a diagnostic bottleneck that the country's colposcopy services were never resourced to absorb. The review released this week is less a story of policy failure than of a recurring human pattern — the gap between the vision of equity and the infrastructure required to honour it.
New Zealand's cervical cancer screening programme is straining under the weight of its own partial success. A review released this week found that the 2023 introduction of at-home HPV tests — genuinely transformative in reaching Māori and Pacific women who had long avoided clinic-based screening — created a surge in referrals that the rest of the system was never built to handle. Colposcopy services, designed for a predictable patient volume, were overwhelmed. Women who tested positive faced delays in the follow-up care needed to determine whether they had precancerous changes or cancer itself.
The review also exposed deep failures in the national screening register, the database meant to guide women through the programme. Clinicians called it clinically unsafe: it could not reliably identify under-screened populations, and it lacked the ability to contact people by email or text — the channels most used by Māori and Pacific communities and by those without fixed addresses. A system intended to reach the hardest-to-reach was, in practice, reaching almost no one in those groups.
The human stakes are not abstract. Between 2018 and 2022, Māori women died from cervical cancer at more than twice the rate of other New Zealanders. The review recommended embedding a Te Tiriti-led co-governance model across the entire programme to address these entrenched inequities — a recommendation that has since become politically contested. Health Minister Simeon Brown rejected the co-governance approach while affirming other fixes; New Zealand First's Winston Peters dismissed the report's framing as ideological overreach; and Labour's Ayesha Verrall, who oversaw the original rollout, conceded that gynaecology services had been chronically underfunded.
Both major parties support universal free cervical screening next year. But the review's central finding remains unaddressed: a screening programme can only deliver on its promise if every stage of it — from the first test to the final diagnosis — is resourced to meet the demand it creates.
New Zealand's cervical cancer screening system is buckling under the weight of its own success. A damning review released this week has exposed a critical mismatch: the introduction of at-home HPV tests in 2023 dramatically increased the number of women seeking screening, particularly among Māori and Pacific communities who had been historically underserved. But the infrastructure to handle what came next—the colposcopy appointments and cytology tests needed to rule out cancer in those who tested positive—was never built.
The HPV self-tests themselves were genuinely transformative. Women could test privately at home, without the barriers of clinic visits or the discomfort that had kept many away from screening altogether. The tests identify high-risk HPV strains before abnormal cells necessarily develop. Uptake surged among groups that had long been missed by the old system. For a moment, it looked like a public health win.
Then the referrals came. One unnamed screening provider told the review authors what many were thinking: the system was "set up to fail." Colposcopy clinics, designed for a certain volume of patients, found themselves overwhelmed. The anticipated surge in demand from the HPV rollout was never matched with additional staff, equipment, or appointment slots. Women who tested positive faced delays in getting the follow-up care they needed to determine whether they had precancerous changes or cancer itself. The very success of the screening test had created a bottleneck in diagnosis.
The review also turned its attention to the national screening register, the database meant to track women through the system and send appointment reminders. Clinicians described it as clinically unsafe. It struggled to identify which women belonged to under-screened populations. Worse, it could not contact people by email or text—the preferred methods for Māori and Pacific communities and for people without a fixed address. A system designed to reach the hardest-to-reach was, in practice, reaching almost no one.
The human cost of these failures is stark. Between 2018 and 2022, Māori women died from cervical cancer at more than twice the rate of other New Zealanders. The review emphasised this disparity throughout, recommending a Te Tiriti-led co-governance model be embedded across the entire programme to address the health inequities baked into screening access and outcomes.
That recommendation has become politically fraught. New Zealand First leader Winston Peters attacked the report's language and framing, calling it "pervasive and arrogant wokeness." Health Minister Simeon Brown, who has already criticised the 2023 HPV rollout as rushed, said he disagreed with the co-governance approach but confirmed the Government was implementing other recommendations, particularly around colposcopy access and wait times. Labour's health spokeswoman Ayesha Verrall, who oversaw the HPV rollout as minister, acknowledged the tests had succeeded in increasing uptake but said the next step—adequate gynaecology resourcing—had been chronically underfunded.
Both major parties support rolling out universal free cervical screening next year, regardless of the election outcome. But the review's core finding remains unresolved: a screening system can only work if every part of it is resourced to handle the demand it creates. Right now, New Zealand's is not.
Citações Notáveis
Colposcopy is overwhelmed with referrals since change of screening; the anticipated change was never resourced and therefore we were set up to fail the women we are providing care to— Unnamed screening provider quoted in the review
In my view, that has been an area where under-resourcing has been particularly acute— Labour health spokeswoman Ayesha Verrall, on gynaecology services
Quer a matéria completa?
Leia o original em NZ Herald ↗
Health & Medicine